Chiome Bioscience (TSE:4583) 3-Year FCF Growth Rate : 17.10% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience 3-Year FCF Growth Rate?

Chiome Bioscience's Free Cash Flow per Share for the three months ended in Mar. 2024 was 円0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 17.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 19.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Chiome Bioscience was 23.60% per year. The lowest was -168.20% per year. And the median was -1.75% per year.

Competitive Comparison of Chiome Bioscience's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Chiome Bioscience's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chiome Bioscience's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's 3-Year FCF Growth Rate falls into.

Chiome Bioscience 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Chiome Bioscience (TSE:4583) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Chiome Bioscience 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiome Bioscience (TSE:4583) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071

Website

http://www.chiome.co.jp

Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines